Novel strategies to attenuate immune activation in Crohn's disease

2006 ◽  
Vol 6 (4) ◽  
pp. 401-407 ◽  
Author(s):  
G BAMIAS ◽  
F COMINELLI
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Immune Activation

Immune activation and nutritional status in adult Crohn's disease patients

2005 ◽  
Vol 37 (6) ◽  
pp. 424-431 ◽  
Author(s):  
J.-M. Reimund ◽  
Y. Arondel ◽  
G. Escalin ◽  
G. Finck ◽  
R. Baumann ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Nutritional Status ◽  
Immune Activation

P087 ILEAL BIOMARKER OF INNATE IMMUNE ACTIVATION CAN PREDICT CLINICAL RESPONSE TO VEDOLIZUMAB IN CROHN’S DISEASE

2019 ◽  
Vol 25 (Supplement_1) ◽  
pp. S41-S41 ◽  
Author(s):  
Mark T Osterman ◽  
Ilyssa O Gordon ◽  
Elisabeth M Davis ◽  
Matthew A Ciorba ◽  
Sarah C Glover ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Clinical Response ◽  
Immune Activation ◽  
Innate Immune ◽  
Innate Immune Activation

Mucosal Biomarker of Innate Immune Activation Predicts Response to Vedolizumab in Crohn’s Disease

2019 ◽  
Author(s):  
Mark T Osterman ◽  
Ilyssa O Gordon ◽  
Elisabeth M Davis ◽  
Matthew Ciorba ◽  
Sarah C Glover ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Clinical Response ◽  
Immune Activation ◽  
Clinical Remission ◽  
Response Rate ◽  
Intestinal Inflammation ◽  
Innate Immune ◽  
Clinical Response Rate ◽  
Innate Immune Activation

Abstract Objective Mucosal barrier dysfunction plays a crucial role in intestinal inflammation in Crohn’s disease (CD). Intestinal epithelial cell (IEC) death resulting from innate immune activation, termed pyroptosis, was recently found to be a cause of this barrier defect. The aim of this study was to determine the predictive value of pretreatment ileal biopsy pyroptosis as a biomarker for clinical response to vedolizumab in CD. Design Crohn’s disease patients ranging 18 to 80 years old from 5 IBD centers with pre-vedolizumab ileal biopsies during colonoscopy were enrolled. Biopsies were stained for activated caspases, and levels of ileal IEC pyroptosis levels were quantified. The primary outcome was clinical response 6 months after therapy, defined as a reduction of Harvey-Bradshaw Index (HBI) of ≥5 points from baseline. Secondary outcomes included clinical remission, defined as HBI <5, and endoscopic improvement, as measured by the Simple Endoscopic Score for Crohn’s Disease (SES-CD). Results One hundred CD patients (45 male, 55 female), median age 47 (19, 78) years, were included; clinical response rate was 60%, and clinical remission was 36%. The response rate in patients with ileal pyroptosis <14 positive cells per 1000 IECs was significantly higher than those above the threshold: 89% (25 of 28) vs 49% (35 of 72), odds ratio (OR) 8.8 (95% CI, 2.3–48.6; P < 0.001). Corresponding remission rates were 54% (15 of 28) vs 29% (21 of 72; OR 2.8 [1.03–7.59; P = 0.036]). For endoscopic improvement, ileal pyroptosis of 22 positive cells per 1000 IECs was the optimal threshold that determines the magnitude SES-CD change. Conclusions Ileal biopsy IEC pyroptosis was predictive of clinical response and endoscopic improvement to vedolizmab in CD patients.

scholarly journals Depressive Symptoms in Crohn's Disease: Relationship with Immune Activation and Tryptophan Availability

PLoS ONE ◽  
2013 ◽  
Vol 8 (3) ◽  
pp. e60435 ◽  
Author(s):  
Sinan Guloksuz ◽  
Marieke Wichers ◽  
Gunter Kenis ◽  
Maurice G. V. M. Russel ◽  
Annick Wauters ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Depressive Symptoms ◽  
Crohn's Disease ◽  
Immune Activation

P087 ILEAL BIOMARKER OF INNATE IMMUNE ACTIVATION CAN PREDICT CLINICAL RESPONSE TO VEDOLIZUMAB IN CROHN’S DISEASE

2019 ◽  
Vol 156 (3) ◽  
pp. S59-S60
Author(s):  
Mark T. Osterman ◽  
Ilyssa O. Gordon ◽  
Elisabeth M. Davis ◽  
Matthew A. Ciorba ◽  
Sarah C. Glover ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Clinical Response ◽  
Immune Activation ◽  
Innate Immune ◽  
Innate Immune Activation

On-table endoscopy to define strictures and resection margins: experience from 178 operations for Crohn's disease using intraoperative endoscopy

2001 ◽  
Vol 3 (Supplement 2) ◽  
pp. 58-62
Author(s):  
G. Olaison ◽  
P. Andersson ◽  
P. Myrelid ◽  
K. Smedh ◽  
J. Soderholm ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Resection Margins ◽  
Intraoperative Endoscopy
Sign in / Sign up

Export Citation Format

Share Document